Последние добавленные видео:
Event:-EHA-2022
-
2 years ago
113 2 years ago 1:27:28The IACH Post ASCO/EHA 2022 Roundtable Discussion: a Focus on Multiple Myeloma
-
3 years ago
1110 3 years ago 4:33Highlights in multiple myeloma at EHA 2022
-
3 years ago
560 3 years ago 1:03CLL trial updates from EHA 2022
-
3 years ago
213 3 years ago 3:15Key updates in CAR-T therapy from EHA 2022
-
3 years ago
568 3 years ago 1:46How Teclistamab Treatment Affects Quality of Life | Rakesh Popat, MD | EHA 2022
-
2 years ago
251 2 years ago 3:02Highlights in AML and MDS from EHA 2022
-
3 years ago
258 3 years ago 5:12Treatment with decitabine resulted in a similar survival and fewer adverse events compared with ...
-
1 year ago
255 1 year ago 1:46:56A tour to EHA 2022
-
3 years ago
44 3 years ago 5:52Session highlights: disparities in hematology care & lessons learned from Ukraine
-
2 years ago
381 2 years ago 12:17Updated IV and SC Results from a Phase I Dose Escalation Study of Forimtamig with RRMM Patients
-
2 years ago
107 2 years ago 20:22Thrombotic events in MPN: Primary prophylaxis to avoid the first arterial and venous events
-
2 years ago
114 2 years ago 3:29The impact of ageing on myeloma disease biology
-
3 years ago
632 3 years ago 4:56Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab Presented at EHA 2022
-
2 years ago
384 2 years ago 25:13EHA 2022 - 2.3. New advocacy initiatives supported by LEV Foundation (Aubrey de Grey)
-
2 years ago
181 2 years ago 12:16The QuANTUM-First study
-
3 years ago
8658 3 years ago 2:00Should the Free Light Chain Ratio be used as a Myeloma Defining Event | Heinz Ludwig, MD | EHA 2022
-
3 years ago
90 3 years ago 7:31A single dose of ctx001shows promising efficacy and safety for TDT and severe SCD
-
5 months ago
68 5 months ago 55:38Updates from ASCO and EHA Meeting 2022 about MDS Research and Treatments